about
Gene therapy for Wiskott-Aldrich Syndrome.Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients.Pioglitazone as a novel therapeutic approach in chronic granulomatous disease.In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution PhasesAlterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients.Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.A novel genomic inversion in Wiskott-Aldrich-associated autoinflammation.Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID.Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency.Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy.First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
P50
Q33417777-376751BC-3CE8-4E92-9F84-273BB235EC2AQ34145125-2FDA083A-0ABA-4740-A347-FC1276567027Q34356904-2FEA069B-1E9C-4EE7-8682-DCA5ED21850BQ35810860-DCF7B9AC-A9C3-4048-82C9-8C5D421E829FQ36958626-B46BBFF1-72FE-4595-90A8-C49923141332Q37089345-5C47032F-9322-4893-B66D-4951A2FC710BQ37578901-675A3140-519F-4A34-9900-356823D83B34Q37664729-F81356B7-07E4-4D63-B3BD-4A6CFFA59BF1Q41404616-E22469C5-7746-4118-8164-58AF3480D420Q42112966-B66BCFE7-BA69-47B2-863F-C891FA35FDA9Q42164387-CCB74461-F163-4C5A-AACE-1CA6D79ACC3CQ43277900-706F3EB7-8FDD-4748-B998-E7F022700758Q45869648-B3EB9885-9256-4475-9408-CC72AFA52444Q45871255-F068DBCC-33F5-4DE1-9712-129054E1F093Q45883238-C2F7F80F-BF74-4A3A-BAF0-85C7417494E1Q49595032-F8E8B9B6-DFC0-4F29-84FB-2EF807FBDFD3Q49884908-B413CEE5-ED49-46C7-B5C6-008E57DAF60DQ50056661-EA38B3F7-9798-42AA-A0CA-ECE4A29544CD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesca Ferrua
@ast
Francesca Ferrua
@en
Francesca Ferrua
@es
Francesca Ferrua
@nl
type
label
Francesca Ferrua
@ast
Francesca Ferrua
@en
Francesca Ferrua
@es
Francesca Ferrua
@nl
prefLabel
Francesca Ferrua
@ast
Francesca Ferrua
@en
Francesca Ferrua
@es
Francesca Ferrua
@nl
P106
P1153
26029821100
P31
P496
0000-0002-5695-4490